PT - JOURNAL ARTICLE AU - Rabe, Brian A AU - Cepko, Constance TI - SARS-CoV-2 Detection Using an Isothermal Amplification Reaction and a Rapid, Inexpensive Protocol for Sample Inactivation and Purification AID - 10.1101/2020.04.23.20076877 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.23.20076877 4099 - http://medrxiv.org/content/early/2020/04/28/2020.04.23.20076877.short 4100 - http://medrxiv.org/content/early/2020/04/28/2020.04.23.20076877.full AB - As the current SARS-CoV-2 pandemic spreads, the need for more diagnostic capabilities is great. In order to address this need, we have developed a highly sensitive RT-LAMP assay compatible with current reagents, that utilizes a colorimetric readout in as little as 30 minutes. In addition to this, we have developed an inexpensive pipeline to further increase sensitivity without requiring highly specialized equipment. A rapid inactivation protocol capable of inactivating virions, as well as endogenous nucleases, was also developed to increase sensitivity and sample stability. This protocol, combined with our RT-LAMP assay, has a sensitivity of at least 50 viral RNA copies per microliter in a sample. To further increase the sensitivity, a purification protocol compatible with this inactivation method was developed. The inactivation and purification protocol, combined with our RT-LAMP assay, brings the sensitivity to at least 1 viral RNA copy per microliter in a sample. We hope that this inactivation and purification pipeline, which costs approximately $0.07 per sample and which uses readily available reagents, will increase the availability of SARS-CoV-2 testing, as well as expand the settings in which this testing can be performed.Competing Interest StatementHarvard University has filed patent applications regarding this technology on behalf of the inventors. Harvard believes strongly that while intellectual property rights serve to incentivize creation of new products, such rights should not become a barrier to addressing urgent and essential health-related needs. To address the global COVID-19 pandemic, Harvard is implementing technology transfer strategies to allow for rapid utilization of available technologies that may be useful for preventing, diagnosing and treating COVID-19 infection. More information can be found at otd.harvard.edu.Funding StatementThis work was supported by the Howard Hughes Medical Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data (real-time thermocycler data or photographs) can be provided upon request.